Reduction of skeletal blood flow in Paget's disease with disodium etidronate therapy

Journal Article · Tue Jan 01 04:00:00 EST 1985 · Bone; (United States)

DOI:https://doi.org/10.1016/8756-3282(85)90403-X· OSTI ID:6241541

Walton, K R; Green, J R; Reeve, J; Wootton, R

Fourteen patients with Paget's disease of bone were treated with disodium etidronate in doses of 5 to 7 mg/kg per day. Skeletal blood flow (SBF), was measured by the modified /sup 18/F clearance technique of Wootton before treatment and again during treatment. In 10 patients restudied 3-4 months after the start of therapy, SBF had fallen by a mean of 21% of the initial value, and the individual differences correlated well with the individual reductions in serum alkaline phosphatase. The results were similar to those seen in an earlier study in patients treated with calcitonin. However, no early reduction in SBF was seen in six repeat studies performed at the end of the second week of treatment, in contrast with our previous findings with calcitonin.

• OSTI ID: 6241541
• Journal Information: Bone; (United States), Journal Name: Bone; (United States) Vol. 1; ISSN BONED
• Country of Publication: United States
• Language: English

Related Subjects

550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
62 RADIOLOGY AND NUCLEAR MEDICINE
ALKALINE PHOSPHATASE
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
BLOOD CHEMISTRY
BLOOD FLOW
BODY
CALCITONIN
DISEASES
DRUGS
ELEMENTS
ENZYMES
ESTERASES
FLUORINE
FLUORINE 18
FLUORINE ISOTOPES
HALOGENS
HORMONES
HOURS LIVING RADIOISOTOPES
HYDROLASES
ISOTOPES
LIGHT NUCLEI
NONMETALS
NUCLEI
ODD-ODD NUCLEI
ORGANIC COMPOUNDS
ORGANS
PATIENTS
PEPTIDE HORMONES
PEPTIDES
PHOSPHATASES
POLYPEPTIDES
PROTEINS
RADIOISOTOPES
SKELETAL DISEASES
SKELETON